NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Tuesday. The brokerage set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets reduced their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Performance

Shares of NBY stock opened at $0.57 on Tuesday. The stock has a fifty day moving average price of $0.67 and a 200 day moving average price of $1.37. The stock has a market cap of $2.80 million, a PE ratio of -0.01 and a beta of 0.69. NovaBay Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $10.64.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.